NAGIOS: RODERIC FUNCIONANDO

Determination of essential biomarkers in lung cancer : a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Determination of essential biomarkers in lung cancer : a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

dc.contributor.author	Provencio Pulla, Mariano
dc.contributor.author	Cobo, Manuel
dc.contributor.author	Rodriguez-Abreu, Delvys
dc.contributor.author	Calvo, Virginia
dc.contributor.author	Carcereny, Enric
dc.contributor.author	Cantero, Alejandra
dc.contributor.author	Bernabé, Reyes
dc.contributor.author	Benítez, Gretel
dc.contributor.author	López Castro, Rafael
dc.contributor.author	Massuti Sureda, Bartomeu
dc.contributor.author	Barco, Edel
dc.contributor.author	Garcia Campelo, Rosario
dc.contributor.author	Guirado, Maria
dc.contributor.author	Camps Herrero, Carlos
dc.contributor.author	Ortega, Ana Laura
dc.contributor.author	González Larriba, Jose Luís
dc.contributor.author	Sánchez, Alfredo
dc.contributor.author	Casal, Joaquín
dc.contributor.author	Sala, M. Angeles
dc.contributor.author	Juan Vidal, Óscar José
dc.contributor.author	Bosch Barrera, Joaquim
dc.contributor.author	Oramas, Juana
dc.contributor.author	Dómine, Manuel
dc.contributor.author	Trigo, Jose Manuel
dc.contributor.author	Blanco, Remei
dc.contributor.author	Calzas, Julia
dc.contributor.author	Morilla, Idoia
dc.contributor.author	Padilla, Airam
dc.contributor.author	Torrente, Maria
dc.date.accessioned	2022-07-19T18:16:27Z
dc.date.available	2022-07-19T18:16:27Z
dc.date.issued	2022
dc.identifier.citation	Provencio Pulla, Mariano Cobo, Manuel Rodriguez-Abreu, Delvys Calvo, Virginia Carcereny, Enric Cantero, Alejandra Bernabé, Reyes Benítez, Gretel López Castro, Rafael Massutí Sureda, Bartomeu Barco, Edel Garcia Campelo, Rosario Guirado, Maria Camps Herrero, Carlos Ortega, Ana Laura González Larriba, Jose Luís Sánchez, Alfredo Casal, Joaquín Sala, M. Angeles Juan Vidal, Oscar Bosch Barrera, Joaquim Oramas, Juana Dómine, Manuel Trigo, Jose Manuel Blanco, Remei Calzas, Julia Morilla, Idoia Padilla, Airam Torrente, Maria 2022 Determination of essential biomarkers in lung cancer : a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics BMC Cancer 22 732
dc.identifier.uri	https://hdl.handle.net/10550/83471
dc.description.abstract	Background The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages and the emergence of immunotherapy itself. This work aims to study the situation of biomarker testing in Spain. Patients and methods The Thoracic Tumours Registry (TTR) is an observational, prospective, registry-based study that included patients diagnosed with lung cancer and other thoracic tumours, from September 2016 to 2020. This TTR study was sponsored by the Spanish Lung Cancer Group (GECP) Foundation, an independent, scientific, multidisciplinary oncology society that coordinates more than 550 experts and 182 hospitals across the Spanish territory. Results Nine thousand two hundred thirty-nine patients diagnosed with stage IV non-small cell lung cancer (NSCLC) between 2106 and 2020 were analysed. 7,467 (80.8%) were non-squamous and 1,772 (19.2%) were squamous. Tumour marker testing was performed in 85.0% of patients with non-squamous tumours vs 56.3% in those with squamous tumours (p-value < 0.001). The global testing of EGFR, ALK, and ROS1 was 78.9, 64.7, 35.6% respectively, in non-squamous histology. PDL1 was determined globally in the same period (46.9%), although if we focus on the last 3 years it exceeds 85%. There has been a significant increase in the last few years of all determinations and there are even close to 10% of molecular determinations that do not yet have targeted drug approval but will have it in the near future. 4,115 cases had a positive result (44.5%) for either EGFR, ALK, KRAS, BRAF, ROS1, or high PDL1. Conclusions Despite the lack of a national project and standard protocol in Spain that regulates the determination of biomarkers, the situation is similar to other European countries. Given the growing number of different determinations and their high positivity, national strategies are urgently needed to implement next-generation sequencing (NGS) in an integrated and cost-effective way in lung cancer.
dc.relation.ispartof	BMC Cancer, 2022, vol. 22, num. 732
dc.subject	Càncer
dc.subject	Pulmons
dc.title	Determination of essential biomarkers in lung cancer : a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
dc.type	journal article	es_ES
dc.date.updated	2022-07-19T18:16:27Z
dc.identifier.doi	10.1186/s12885-022-09830-8
dc.identifier.idgrec	154245
dc.rights.accessRights	open access	es_ES